NCT00062491 - Study of Karenitecin (BNP1350) to Treat Malignant Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

June 30, 2003

Study Completion Date

November 30, 2005

Conditions

MelanomaNeoplasm

Interventions

DRUG

Karenitecin (BNP1350)

Karenitecn (1.0 mg/m2) administered as a single daily 60-minute intravenous infusion for 5 consecutive days repeated every 21 days (1 treatment cycle). Patients who respond (CR\< PR, SD) can continue treatment for 6 cycles, unless unacceptable toxicity develops. Treatment will be discontinued if progressive disease or unacceptable toxicity develops.

Trial Locations (1)

33612

For Information call 210-614-1701 for a site near you, Tampa